Abstract: A method for the patterning and control of single electrons on a surface is provided that includes implementing scanning tunneling microscopy hydrogen lithography with a scanning probe microscope to form charge structures with one or more confined charges; performing a series of field-free atomic force microscopy measurements on the charge structures with different tip heights, where interaction between the tip and the confined charge are elucidated; and adjusting tip heights to controllably position charges within the structures to write a given charge state. The present disclose also provides a Gibb's distribution machine formed with the method for the patterning and control of single electrons on a surface. A multi bit true random number generator and neural network learning hardware formed with the above described method are also provided.

Abstract: Provided are transgenic organisms, such as plants and plant parts, cells, and related compositions and methods for producing and monitoring the genotype for enhanced production of montbretin A and/or its precursors. For example, provided is a transgenic organism comprising at least one heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes at least one enzyme in a montbretin A (MbA) metabolic pathway. The organisms can be a plant, plant part, or plant cell, or a microorganism such as a yeast. Also provided is a method for producing at least one montbretin A (MbA) precursor and/or MbA, comprising permitting the expression of the at least one heterologous nucleic acid in the transgenic organism. The disclosure also provides isolated nucleic acid molecules that comprise sequence encoding at least one enzyme in a montbretin A (MbA) metabolic pathway and vectors comprising the nucleic acids.

Abstract: Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include a sema domain, a structural stabilization domain; and a half life extending moiety.

Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: A method of facilitating ultrasonic analysis of a subject is provided. The method involves producing signals for causing a set of outgoing ultrasonic signals to be transmitted to the subject, wherein the set of outgoing ultrasonic signals is defined at least in part by a variable imaging parameter that varies over time in accordance with a variable imaging parameter function, the variable imaging parameter function represented or representable at least in part by a function characteristic, receiving signals representing a time dependent representation of the subject generated from a set of received ultrasonic signals scattered by the subject, determining at least one property representation of the subject based on the function characteristic and the time dependent representation of the subject, and producing signals representing the at least one property representation of the subject to facilitate analysis of the subject. Systems, non-transitory computer readable media, and other methods are also provided.

Abstract: A computer-implemented system for facilitating echocardiographic image analysis is disclosed. The system includes at least one processor configured to receive signals representing a first at least one echocardiographic image, associate the image with a first view category of a plurality of predetermined view categories, determine, based on the first at least one echocardiographic image and the first view category, a first quality assessment value representing a view category specific quality assessment of the first at least one echocardiographic image, and produce signals representing the first quality assessment value for causing the first quality assessment value to be associated with the first at least one echocardiographic image. The at least one processor may also be configured to do the above steps for a second at least one echocardiographic and a second view category that is different from the first view category image. Other systems, methods, and computer-readable media are also disclosed.

Abstract: The invention relates to administration of clinical anesthesia. Particular embodiments provide systems and methods for controlled delivery of a combination of an analgesic agent and a hypnotic agent. More specifically, the invention relates to closed-loop control systems/methods for automatically controlling the administration of a combination of a hypnotic agent and an analgesic agent in a clinical anesthesia setting which incorporate feedback based on one or more indirect measures/indicia of analgesia. The invention further relates to such control systems/methods that account for limitations of such indirect measures/indicia of analgesia.

Abstract: Provided herein are compositions comprising: a scaffold polymer having one or more acryloyl groups or one or more methacryloyl groups; optionally a porogen and a crosslinking agent, compositions that upon crosslinking form a hydrogel for use in cell encapsulation and methods for immunocytochemistry of encapsulated cells. Scaffold polymers used are selected from: Poly(ethylene glycol) diacrylate (PEGDA); Poly(ethylene glycol) dimethylacrylate (PEGDMA); Poly(ethylene glycol) methyl ether acrylate (PEGMEA); Poly(ethylene glycol) methacrylate (PEGMA); and Poly(ethylene glycol) methyl ether methacrylate (PEGMEMA), and porogens selected from: Poly(ethylene glycol) (PEG); Chitosan; Agarose; Dextran; Hyaluronic acid; Poly(methyl methacrylate) (PMMA); Cellulose and derivatives thereof; Gelatin and derivatives thereof; and Acrylamide and derivatives thereof. The invention also provides, at least in part, compositions for forming a porous hydrogel around a cell suitable for immunostaining of cells within the hydrogel.

Abstract: Microfluidic devices and methods for perfusing a cell with perfusion fluid are provided herein, wherein the gravitational forces acting on the cell to keep the cell at or near a retainer or a retaining position exceed the hydrodynamic forces acting on the cell to move it toward an outlet. Also provided, are methods for assaying cell products within the microfluidic device.

Abstract: Systems and methods for intermedullary bone fracture fixation are described herein. The fixation device includes a main body having a flexible state and a rigid state. The fixation device further includes a proximal interface coupled to a proximal end of the main body to anchor the fixation device to an exterior surface of the bone and a distal interface coupled to a distal end of the main body to anchor the fixation device to an interior cavity of the bone. The fixation device further includes a locking interface to configured to convert the main body from the flexible state to the rigid state.

Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

Abstract: A method for refining lithium from a crude brine includes charging a crude brine into a feeder tank held at a temperature T1 and containing a sufficient carbonate source to precipitate all carbonate-forming solids in the crude brine to form a precipitate mixture and a crystal free supernatant; pumping the crystal free supernatant from the feeder tank to a first crystallization reactor that is held at a temperature T2 to crystallize a lithium carbonate salt out of the crystal free supernatant; wherein the temperature T1 is lower than the temperature T2; and controlling a flow rate to maintain a steady state concentration of the lithium carbonate salt in the solution phase of the crystallization reactor.

Abstract: This application pertains to group 5 metal complexes having the structure of Formula I: and their potential utility in catalyzing ?-alkylation of secondary amine-containing moieties.

Abstract: An actuator device includes a housing that defines an enclosed volume region, the housing comprising a movable surface such that at least a portion of the housing is expandable between an expanded state to a contracted state, and the enclosed volume region having a characteristic dimension that is defined as a cube root of an average of a volume of the enclosed volume region in the expanded state and in the contracted state, a working fluid within the enclosed volumetric region, the working fluid comprising a substantially transparent compressible fluid and electromagnetic (EM) radiation-absorbing solid elements distributed within the compressible fluid, wherein the solid elements have an absorptivity in a particular range of EM radiation wavelengths, a heating system for directing thermal energy into the working fluid at predetermined times, and wherein the housing includes an EM radiation transmitting portion having a sufficient area and a sufficient transparency such that more than 25% of the thermal energ

Abstract: The present disclosure relates to methods of diagnosing acute rejection of a cardiac allograft in a subject using genomic expression profiling, proteomic expression profiling, or both on panels of nucleic acid markers and proteomic markers.

Abstract: The present disclosure is directed towards improved systems and methods for large-scale production of nanoparticles used for delivery of therapeutic material. The apparatus can be used to manufacture a wide array of nanoparticles containing therapeutic material including, but not limited to, lipid nanoparticles and polymer nanoparticles. In certain embodiments, continuous flow operation and parallelization of microfluidic mixers contribute to increased nanoparticle production volume.

Abstract: Systems and methods for intermedullary bone fracture fixation are described herein. The fixation device includes a main body having a flexible state and a rigid state. The fixation device further includes a proximal interface coupled to a proximal end of the main body to anchor the fixation device to an exterior surface of the bone and a distal interface coupled to a distal end of the main body to anchor the fixation device to an interior cavity of the bone. The fixation device further includes a locking interface to configured to convert the main body from the flexible state to the rigid state.

Abstract: This application pertains to methods of recovering metals from metal sulfides that involve contacting the metal sulfide with an acidic sulfate solution containing ferric sulfate and a reagent that has a thiocarbonyl functional group, wherein the concentration of reagent in the acidic sulfate solution is sufficient to increase the rate of metal ion extraction relative to an acidic sulfate solution that does not contain the reagent, to produce a pregnant solution containing the metal ions.

Abstract: A displacement device includes a stator having non-parallel stator-x and stator-y elongated traces. The device also includes a moveable stage having a first magnet array with first magnetization segments linearly elongated in a stage-x direction and having magnetization directions generally orthogonal to the stage-x direction. The first magnet array includes a first pair of adjacent first magnetization segments made up of two first magnetization segments adjacent to one another in a stage-y direction non-parallel to the stage-x direction. Each first magnetization segment in the first pair has a corresponding magnetization direction oriented at a corresponding angle ?n about a corresponding stage-x axis as measured from a positive stage-z direction that is generally orthogonal to both the stator-x and stator-y directions. The corresponding angle ?n is one of 45°+n90° where n is any integer. Each first magnetization segment in the first pair has a different magnetization direction.

Abstract: This application pertains to methods of recovering metals from metal sulfides that involve contacting the metal sulfide with an acidic sulfate solution containing ferric sulfate and a reagent that has a thiocarbonyl functional group, wherein the concentration of reagent in the acidic sulfate solution is sufficient to increase the rate of metal ion extraction relative to an acidic sulfate solution that does not contain the reagent, to produce a pregnant solution containing the metal ions.